BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 11486026)

  • 1. c-Abl regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination.
    Sionov RV; Coen S; Goldberg Z; Berger M; Bercovich B; Ben-Neriah Y; Ciechanover A; Haupt Y
    Mol Cell Biol; 2001 Sep; 21(17):5869-78. PubMed ID: 11486026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MDM2 RING-finger domain is required to promote p53 nuclear export.
    Geyer RK; Yu ZK; Maki CG
    Nat Cell Biol; 2000 Sep; 2(9):569-73. PubMed ID: 10980696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.
    Rodriguez MS; Desterro JM; Lain S; Lane DP; Hay RT
    Mol Cell Biol; 2000 Nov; 20(22):8458-67. PubMed ID: 11046142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation.
    Alarcón R; Koumenis C; Geyer RK; Maki CG; Giaccia AJ
    Cancer Res; 1999 Dec; 59(24):6046-51. PubMed ID: 10626788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding.
    Inoue T; Geyer RK; Howard D; Yu ZK; Maki CG
    J Biol Chem; 2001 Nov; 276(48):45255-60. PubMed ID: 11572869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage.
    Joseph TW; Zaika A; Moll UM
    FASEB J; 2003 Sep; 17(12):1622-30. PubMed ID: 12958168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2-dependent ubiquitination of nuclear and cytoplasmic P53.
    Yu ZK; Geyer RK; Maki CG
    Oncogene; 2000 Nov; 19(51):5892-7. PubMed ID: 11127820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of p53 ubiquitination and nuclear export by MDM2 and ARF.
    Zhang Y; Xiong Y
    Cell Growth Differ; 2001 Apr; 12(4):175-86. PubMed ID: 11331246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53.
    Xirodimas DP; Stephen CW; Lane DP
    Exp Cell Res; 2001 Oct; 270(1):66-77. PubMed ID: 11597128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation.
    Stommel JM; Wahl GM
    EMBO J; 2004 Apr; 23(7):1547-56. PubMed ID: 15029243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The contribution of the acidic domain of MDM2 to p53 and MDM2 stability.
    Argentini M; Barboule N; Wasylyk B
    Oncogene; 2001 Mar; 20(11):1267-75. PubMed ID: 11313871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.
    Honda R; Tanaka H; Yasuda H
    FEBS Lett; 1997 Dec; 420(1):25-7. PubMed ID: 9450543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6.
    Freedman DA; Levine AJ
    Mol Cell Biol; 1998 Dec; 18(12):7288-93. PubMed ID: 9819415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The p53-Mdm2 module and the ubiquitin system.
    Michael D; Oren M
    Semin Cancer Biol; 2003 Feb; 13(1):49-58. PubMed ID: 12507556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-Abl as a modulator of p53.
    Levav-Cohen Y; Goldberg Z; Zuckerman V; Grossman T; Haupt S; Haupt Y
    Biochem Biophys Res Commun; 2005 Jun; 331(3):737-49. PubMed ID: 15865930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supramolecular complex formation between Rad6 and proteins of the p53 pathway during DNA damage-induced response.
    Lyakhovich A; Shekhar MP
    Mol Cell Biol; 2003 Apr; 23(7):2463-75. PubMed ID: 12640129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding.
    Wang W; Takimoto R; Rastinejad F; El-Deiry WS
    Mol Cell Biol; 2003 Mar; 23(6):2171-81. PubMed ID: 12612087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2.
    Li M; Brooks CL; Wu-Baer F; Chen D; Baer R; Gu W
    Science; 2003 Dec; 302(5652):1972-5. PubMed ID: 14671306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-Abl phosphorylates Hdmx and regulates its interaction with p53.
    Zuckerman V; Lenos K; Popowicz GM; Silberman I; Grossman T; Marine JC; Holak TA; Jochemsen AG; Haupt Y
    J Biol Chem; 2009 Feb; 284(6):4031-9. PubMed ID: 19075013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
    Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
    Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.